Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Fundãçao Oswaldo Cruz currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, BUCKMASTER, MARLENE VRENI. The prosecution is located within 1 distinct art unit, which indicates a specific technical focus for the company's current intellectual property efforts. This structure means that the practitioner's interactions are limited to a centralized point of contact for all current filings at the patent office.
The busiest examiner identified in the data is BUCKMASTER, MARLENE VRENI, who holds 1 busiest examiner pending action. This count represents the entirety of the foundation's current pending workload. Because the portfolio involves only the identified examiner and art unit in its pending cases, the strategy does not currently require managing multiple procedural standards. The 1 pending office action in Biotechnology & Pharmaceuticals serves as the primary focal point for the foundation's near-term patent acquisition goals at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUCKMASTER, MARLENE VRENI | 1 | 28.1% | +74.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638108 | PROTEIN RECEPTACLE, POLYNUCLEOTIDE, VECTOR, EXPRESSION CASSETTE, CELL, METHOD FOR PRODUCING THE RECEPTACLE, METHOD OF IDENTIFYING PATHOGENS OR DIAGNOSING DISEASES, USE OF THE RECEPTACLE AND DIAGNOSTIC KIT | BUCKMASTER, MARLENE VRENI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638108 | PROTEIN RECEPTACLE, POLYNUCLEOTIDE, VECTOR, EXPRESSION CASSETTE, CELL, METHOD FOR PRODUCING THE RECEPTACLE, METHOD OF IDENTIFYING PATHOGENS OR DIAGNOSING DISEASES, USE OF THE RECEPTACLE AND DIAGNOSTIC KIT | BUCKMASTER, MARLENE VRENI | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17638108 | PROTEIN RECEPTACLE, POLYNUCLEOTIDE, VECTOR, EXPRESSION CASSETTE, CELL, METHOD FOR PRODUCING THE RECEPTACLE, METHOD OF IDENTIFYING PATHOGENS OR DIAGNOSING DISEASES, USE OF THE RECEPTACLE AND DIAGNOSTIC KIT | BUCKMASTER, MARLENE VRENI | 1672 | §102§103§112 | Non-Final OA | — | Pending | Feb 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFundãçao Oswaldo Cruz has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marlene Vreni Buckmaster has the most, with 1 of Fundãçao Oswaldo Cruz's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
